Ketamine psychedelic psychotherapy (KPP) is a treatment approach that combines the dissociative anesthetic ketamine with psychotherapy. Ketamine produces a range of effects including analgesic, sedative, anxiolytic, antidepressant, and hallucinogenic properties. The paper reviews clinical applications of KPP, offers practical guidance, and examines the pharmacology and phenomenology of ketamine-induced experiences, including their potential for transpersonal healing and risks of misuse. It aims to serve as an authoritative resource for psychiatrists and others interested in understanding and applying KPP.
Ketamine, a dissociative anesthetic, has antidepressant effects and can induce transformative transpersonal experiences. Although only approved as an anesthetic in the US, it is prescribed off-label for psychological problems and used similarly in Argentina, Iran, Mexico, Russia, and the UK. The literature on ketamine-enhanced psychotherapy (KEP) is reviewed, and two case studies treating death anxiety in terminally-ill people are reported. The authors emphasize the need for formal research on KEP for end-of-life death anxiety.
Novel psychoactive substances (NPS) are synthetic drugs not under international control, often sold as alternatives to classic street drugs like ecstasy or LSD. Their pharmacology and toxicity are poorly understood, posing unknown health risks. Users frequently do not know what they are taking, making dose, potency, and other properties unpredictable, which elevates the risk for harms.